Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Patent ‘Plausibility’: Landmark Lyrica Case May Get Supreme Court Ruling By Early Summer

Executive Summary

Companies looking forward to a ruling from the Supreme Court on “plausibility” in the UK case involving second medical use patents may have to wait until May or June.

You may also be interested in...



UK Court Ruling A Blow For Pfizer And A Warning For Patentees

A UK Supreme Court decision to invalidate Pfizer's pregabalin patent is not only bad news for Pfizer and good news for the generics firms involved – it could also mean that companies have to produce more evidence to substantiate their patent claims in future.

Pfizer Plays Up Its In-house Potential, Avoids M&A Talk

Pfizer execs say they are focused on commercial execution and pipeline development to drive growth. No viable buyer has emerged for the consumer business, CEO Read said.

The Return Of Second Medical Use Patents: Encouraging R&D Or Stifling Innovation?

Industry is eagerly awaiting this month’s judgement of the UK Supreme Court on whether a rule that constitutes a serious obstacle to enforcing patents for important medicines will be removed or modified, say legal experts Charlotte Tillett and Camille Arnold.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM011995

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel